Status: current, Primitive. Date: 31-Jul 2021. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4550516012 | Tepotinib hydrochloride | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 4550517015 | Tepotinib hydrochloride (substance) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Tepotinib hydrochloride | Is a | Antineoplastic agent | false | Inferred relationship | Some | ||
| Tepotinib hydrochloride | Is a | Enzyme inhibitor | false | Inferred relationship | Some | ||
| Tepotinib hydrochloride | Is modification of | Tepotinib | true | Inferred relationship | Some | ||
| Tepotinib hydrochloride | Has disposition | Protein-tyrosine kinase inhibitor | false | Inferred relationship | Some | ||
| Tepotinib hydrochloride | Is a | Piperidine | true | Inferred relationship | Some | ||
| Tepotinib hydrochloride | Is a | Protein-tyrosine kinase inhibitor | false | Inferred relationship | Some | ||
| Tepotinib hydrochloride | Is a | Mesenchymal epithelial transition inhibitor | true | Inferred relationship | Some | ||
| Tepotinib hydrochloride | Has disposition | Mesenchymal epithelial transition inhibitor | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Tepotinib (as tepotinib hydrochloride) 225 mg oral tablet | Has precise active ingredient | True | Tepotinib hydrochloride | Inferred relationship | Some | 1 |
Reference Sets
Substance foundation reference set
FHIR